I just read an interesting post on the Yahoo board
Post# of 148166
We've all been expressing angst and concern regarding the low power of the 50 subject interim look at the P3 S/C trial.
With CytoDyn having a really good idea of those results no later than yesterday (and probably last week, if not earlier), why would CytoDyn ever agree to a 25 subject Mexico trial having the exact same protocol and a much lower intrinsic power (25 vs 50), if they didn't think it would generate results that could lead to approval?